Travere Therapeutics Inc Forecast, price target & analysts
Travere Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Travere Therapeutics Inc Classifications & Recommendation:
Travere Therapeutics Inc Price Target
| Target Price | $34.64 |
| Price | $20.64 |
| Potential |
67.84%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Travere Therapeutics Inc 2026 .
The average Travere Therapeutics Inc target price is $34.64.
This is
67.84%
register free of charge
$47.00
127.71%
register free of charge
$22.00
6.59%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Travere Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Travere Therapeutics Inc stock has an average upside potential 2026 of
67.84%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 233.18 | 384.15 |
| 60.55% | 64.74% | |
| EBITDA Margin | -91.19% | -9.98% |
| 60.84% | 89.06% | |
| Net Margin | -153.01% | -27.41% |
| 44.02% | 82.09% |
14 Analysts have issued a sales forecast Travere Therapeutics Inc 2025 . The average Travere Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Travere Therapeutics Inc EBITDA forecast 2025. The average Travere Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Travere Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Travere Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.08 | -1.20 |
| 10.13% | 70.59% | |
| P/E | negative | |
| EV/Sales | 4.85 |
12 Analysts have issued a Travere Therapeutics Inc forecast for earnings per share. The average Travere Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Travere Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Travere Therapeutics Inc...
Current Travere Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan | Locked ➜ Locked | Locked | Feb 26 2025 |
| Citigroup | Locked ➜ Locked | Locked | Feb 24 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Feb 21 2025 |
| Evercore ISI Group | Locked ➜ Locked | Locked | Feb 12 2025 |
| Scotiabank | Locked ➜ Locked | Locked | Feb 12 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Feb 12 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Citigroup: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Evercore ISI Group: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Scotiabank: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Feb 12 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
